Pharma BD Deal Intelligence
FTC required Sun and Ranbaxy to divest generic minocycline assets to Torrent before closing, citing reduced competition risk in three dosage strengths.
Emkay analysts flagged Halol approval uncertainty, generic Gleevec launch timing, and Ranbaxy India acute therapy integration as near-term concerns;…
Sun paid $485M to settle Ranbaxy-inherited antitrust litigation tied to delayed generic Nexium and Lipitor — a tail liability that bit four years post-close.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sun Pharma completed the all-share acquisition of Ranbaxy from Daiichi Sankyo (which held 63.4%) on March 25, 2015 in a $4B transaction (announced April 7, 2014), creating the world's fifth-largest generic drug maker. Each Ranbaxy share exchanged for 0.8 Sun Pharma share.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited (this deal) | 2015 | $4.0B | 52 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2014 | $4.0B | 66 |
| Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc. | 2012 | $230M | 49 |
| Sun Pharmaceutical Industries Ltd. / URL Pharma, Inc. (generics business) | 2012 | $60M | 34 |
| Sun Pharmaceutical Industries Ltd. / Organon & Co. | 2026 | $11.8B | — |
| Sun Pharmaceutical Industries Ltd. / Checkpoint Therapeutics, Inc. | 2025 | $355M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
← Browse all deals · How we score deals
More: 2015 deals · Sun Pharmaceutical Industries Ltd. deals · Other deals